Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL), an early commercial stage biopharmaceutical company focused on programmed T cell therapies, has scheduled its Q1 2025 financial results announcement for May 8, 2025, before US markets open. The company will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss financial performance and provide a business update. Participants must pre-register to receive dial-in details and a personal PIN for the conference call. A simultaneous audio webcast and replay will be available on the company's website events section.
Positive
- None.
Negative
- None.
News Market Reaction – AUTL
On the day this news was published, AUTL gained 11.11%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025.
Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
Olivia Manser
+44 7780 471 568
o.manser@autolus.com
FAQ
When will Autolus Therapeutics (AUTL) release its Q1 2025 earnings?
How can investors join the Autolus Therapeutics (AUTL) Q1 2025 earnings call?
What time is the Autolus Therapeutics (AUTL) Q1 2025 earnings conference call?
Where can I access the replay of AUTL's Q1 2025 earnings call?
